Last updated on February 2017

A Study to Evaluate the Pharmacokinetics Safety and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis


Brief description of study

This is a Phase 3, 2-part (Part A and Part B), open label, multicenter study evaluating the PK, safety, and tolerability of multiple doses of VX-661 in combination with ivacaftor in subjects 6 through 11 years of age with CF who are homozygous or heterozygous for the F508del-CFTR mutation.

Clinical Study Identifier: NCT02953314

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Medical Information

Aurora, CO United States
  Connect »

Medical Information

Atlanta, GA United States
  Connect »

Medical Information

Indianapolis, IN United States
  Connect »

Medical Information

Kansas City, KS United States
  Connect »

Medical Information

Boston, MA United States
  Connect »

Medical Information

Charleston, SC United States
  Connect »

Medical Information

Austin, TX United States
  Connect »

Medical Information

Norfolk, VA United States
  Connect »

Medical Information

Seattle, WA United States
  Connect »

Medical Information

Milwaukee, WI United States
  Connect »